logo

For the Inventor, By the Inventor

Rancho Santa Fe, CA, United States of America

Lawrence C Fritz

This inventor holds 11 USPTO granted patents and 2 published patent applications. Top assignees: Idun Pharmaceuticals, Inc., Conforma Therapeutics Corporation. Active years: 2001-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lawrence C Fritz. Retrieved from https://idiyas.com/inventor/lawrence-c-fritz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 72.7

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 87(Granted Patents)


Company Filing History:

goldMedal10 out of 33 
 
Idun Pharmaceuticals, Inc.
 patents
silverMedal1 out of 10 
 
Conforma Therapeutics Corporation
 patents

Years Active: 2001-2008

Loading Chart...
11 patents (USPTO):Explore Patents
1. 7465718 - Ansamycins having improved pharmacological and biological properties (2008-12-16),
2. 6762045 - Membrane derived caspase-3, compositions comprising the same and methods of use therefor (2004-07-13),
3. 6693096 - Treatment of inflammation-associated disorders using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2004-02-17),
4. 6610683 - Treatment of infectious disease using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-08-26),
5. 6531467 - Inhibition of inflammation using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-11),
6. 6528506 - Inhibition of apoptosis using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-04),
7. 6518032 - Rapid methods for identifying modifiers of cellular apoptosis activity (2003-02-11),
8. 6391575 - Methods for detecting membrane derived caspase activity and modulators thereof (2002-05-21),
9. 6270980 - Rapid methods for identifying modifiers of cellular apoptosis activity (2001-08-07),
10. 6251614 - Rapid methods for identifying modifiers of cellular apoptosis activity (2001-06-26),
11. 6200969 - Inhibition of apoptosis using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2001-03-13),

Title: Innovations and Contributions of Lawrence C. Fritz

Introduction

Lawrence C. Fritz is a notable inventor based in Rancho Santa Fe, California. He has made significant contributions to the field of pharmaceuticals, holding a total of 11 patents. His work primarily focuses on improving pharmacological and biological properties of various compounds.

Latest Patents

Among his latest patents, one notable invention is related to ansamycins. These ansamycins exhibit improved aqueous formulation ability, chemical stability, and bioavailability. Some derivatives described in this patent include dimers, which can incorporate solubilizing groups to enhance their utility as drugs and prodrugs. Another significant patent involves membrane-derived caspase-3, which includes isolated nucleic acids encoding a novel polypeptide. This invention has potential applications in treating pathological disorders caused by altered apoptosis, such as autoimmune diseases, cancer, and infections.

Career Highlights

Lawrence C. Fritz has worked with several prominent companies in the pharmaceutical industry. Notably, he has been associated with Idun Pharmaceuticals, Inc. and Conforma Therapeutics Corporation. His work in these organizations has contributed to advancements in drug development and therapeutic applications.

Collaborations

Throughout his career, Lawrence has collaborated with esteemed colleagues, including Kevin J. Tomaselli and Steven D. Linton. These collaborations have fostered innovation and have been instrumental in the development of his patented technologies.

Conclusion

Lawrence C. Fritz's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence advancements in drug development and therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…